TY  - JOUR

T1  - Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

JO  - British Journal of Dermatology

UR  - http://dx.doi.org/10.1093/bjd/ljad240

PY  - 2023/07/18

AU  - Weidinger S

AU  - Bieber T

AU  - Cork MJ

AU  - Reich A

AU  - Wilson R

AU  - Quaratino S

AU  - Stebegg M

AU  - Brennan N

AU  - Gilbert S

AU  - O’Malley JT

AU  - Porter-Brown B

ED  - 

DO  - DOI: 10.1093/bjd/ljad240

PB  - Oxford University Press (OUP)

VL  - 189

IS  - 5

SP  - 531

EP  - 539

Y2  - 2024/12/22

ER  -